| __timestamp | Ligand Pharmaceuticals Incorporated | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 5078000000 |
| Thursday, January 1, 2015 | 24378000 | 4717000000 |
| Friday, January 1, 2016 | 26621000 | 5096000000 |
| Sunday, January 1, 2017 | 28653000 | 4986000000 |
| Monday, January 1, 2018 | 37734000 | 4214000000 |
| Tuesday, January 1, 2019 | 41884000 | 3806000000 |
| Wednesday, January 1, 2020 | 64435000 | 3671000000 |
| Friday, January 1, 2021 | 57483000 | 3528000000 |
| Saturday, January 1, 2022 | 70062000 | 3445000000 |
| Sunday, January 1, 2023 | 52790000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Unleashing insights
In the ever-evolving pharmaceutical industry, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, Teva's SG&A expenses have shown a downward trend, decreasing by approximately 32% from 2014 to 2023. In contrast, Ligand Pharmaceuticals experienced a significant increase of around 134% in their SG&A expenses, reflecting their strategic investments in growth and expansion.
Teva's peak SG&A expenses were recorded in 2014, while Ligand's expenses reached their zenith in 2022. This divergence highlights the distinct strategic approaches of these companies in managing operational costs. As the pharmaceutical landscape continues to shift, understanding these financial dynamics offers valuable insights into the industry's future direction.
Teva Pharmaceutical Industries Limited vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Teva Pharmaceutical Industries Limited or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Bausch Health Companies Inc. Trends and Insights
Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated: A Detailed Gross Profit Analysis
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ligand Pharmaceuticals Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Opthea Limited and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: TG Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Ligand Pharmaceuticals Incorporated
Vericel Corporation and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Ligand Pharmaceuticals Incorporated and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared